Mounting evidence suggests that genetic ablation of Fxr in the gut or gut-restricted chemical antagonism of the FXR promotes beneficial health effects, including the prevention of nonalcoholic fatty liver disease in rodent models. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.